Key Insights

Highlights

Success Rate

100% trial completion (above average)

Treatment Research

4 treatments under study, led by Erlotinib

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 30/100

Termination Rate

0.0%

0 terminated out of 1 trials

Success Rate

100.0%

+13.4% vs benchmark

Late-Stage Pipeline

100%

1 trials in Phase 3/4

Results Transparency

0%

0 of 1 completed with results

Key Signals

100% success

Data Visualizations

Phase Distribution

1Total
Phase 4 (1)

Trial Status

Completed1

Trial Success Rate

100.0%

Benchmark: 86.6%

Based on 1 completed trials

Clinical Trials (1)

Showing 1 of 1 trials
NCT01402089Phase 4Completed

Cytochrom p450 3A4 and 1A2 Phenotyping for the Individualization of Treatment With Sunitinib or Erlotinib in Cancer Patients

Showing all 1 trials

Research Network

Common Treatments

  • Erlotinib1
  • Midazolam1
  • Sunitinib1
  • Caffeine1

Active Sponsors

  • Markus Joerger1
  • University of Basel1

Top Investigators

Related Conditions

  • Non Smallcell Lung Cancer1
  • Gastrointestinal Stroma Tumor1

Activity Timeline